Cargando…

Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients

BACKGROUND: Post-transplant hyperuricemia (PTHU), defined as serum uric acid concentration ≥7.0 mg/dL or need for treatment with allopurinol or benzbromarone, reduces long-term allograft survival in kidney transplant recipients. Febuxostat, a new nonpurine selective xanthine oxidase inhibitor, is we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sofue, Tadashi, Inui, Masashi, Hara, Taiga, Nishijima, Yoko, Moriwaki, Kumiko, Hayashida, Yushi, Ueda, Nobufumi, Nishiyama, Akira, Kakehi, Yoshiyuki, Kohno, Masakazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933431/ https://www.ncbi.nlm.nih.gov/pubmed/24600205 http://dx.doi.org/10.2147/DDDT.S56597

Ejemplares similares

Plasmapheresis in a patient with antiphospholipid syndrome before living-donor kidney transplantation: a case report
por: Sofue, Tadashi, et al.
Publicado: (2014)

Circadian rhythm of plasma and urinary angiotensinogen in healthy volunteers and in patients with chronic kidney disease
por: Nishijima, Yoko, et al.
Publicado: (2014)

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
por: Akimoto, Tetsu, et al.
Publicado: (2014)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

G Protein-Coupled Receptor 87 (GPR87) Promotes Cell Proliferation in Human Bladder Cancer Cells
por: Zhang, Xia, et al.
Publicado: (2015)

Changes in Prevalence and Health Checkup Coverage Rate of Chronic Kidney Disease (CKD) after Introduction of Prefecture-Wide CKD Initiative: Results of the Kagawa Association of CKD Initiatives
por: Sofue, Tadashi, et al.
Publicado: (2021)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

Comparison of efficacy and safety between febuxostat and allopurinol in early post‐renal transplant recipients with new onset of hyperuricemia
por: Shen, Xiaoju, et al.
Publicado: (2018)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Early Treatment With Olmesartan Prevents Juxtamedullary Glomerular Podocyte Injury and the Onset of Microalbuminuria in Type 2 Diabetic Rats
por: Sofue, Tadashi, et al.
Publicado: (2012)

SAT-079 Renal Protective Effects Of Topiroxostat And Febuxostat In Hypertensives With Hyperuricemia.
por: Satoh, Fumitoshi, et al.
Publicado: (2019)

Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
por: Kario, Kazuomi, et al.
Publicado: (2021)

The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia
por: Tang, Yushang, et al.
Publicado: (2022)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Retracted: The Effects of Febuxostat on Urine NGAL and Urine KIM-1 in Patients with Hyperuricemia
por: Healthcare Engineering, Journal of
Publicado: (2023)

Transplant Prognosis in Kidney Transplant Recipients with Diabetes under Mycophenolic Acid-Focused Therapeutic Drug Monitoring
por: Nakamura, Eisuke, et al.
Publicado: (2021)

Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: A systematic review and meta-analysis
por: Liu, Xuzhong, et al.
Publicado: (2018)

The Effect of Steep Trendelenburg Positioning on Retinal Structure and Function during Robotic-Assisted Laparoscopic Procedures
por: Hirooka, Kazuyuki, et al.
Publicado: (2018)

Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice
por: Yisireyili, Maimaiti, et al.
Publicado: (2017)

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Changeover Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease: Sub-Analysis for Chronic Kidney Disease (TROFEO CKD Trial)
por: Sezai, Akira, et al.
Publicado: (2019)

Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease
por: Tsuruta, Yuki, et al.
Publicado: (2014)

Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
por: Kim, Sollip, et al.
Publicado: (2017)

Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3∼5 with Hyperuricemia
por: Liao, Zhimin, et al.
Publicado: (2022)

Cardio-renal protective effect of the xanthine oxidase inhibitor febuxostat in the 5/6 nephrectomy model with hyperuricemia
por: Omizo, Hiroki, et al.
Publicado: (2020)

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
por: Stack, Austin G, et al.
Publicado: (2020)

Induction of G(2)/M arrest and apoptosis through mitochondria pathway by a dimer sesquiterpene lactone from Smallanthus sonchifolius in HeLa cells
por: Kitai, Yurika, et al.
Publicado: (2016)

Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study
por: Kusunose, Kenya, et al.
Publicado: (2021)

Long-Term Effect of Febuxostat on Endothelial Function in Patients With Asymptomatic Hyperuricemia: A Sub-Analysis of the PRIZE Study
por: Maruhashi, Tatsuya, et al.
Publicado: (2022)

Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder
por: Okazoe, Homare, et al.
Publicado: (2013)

Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study
por: Gunawardhana, Lhanoo, et al.
Publicado: (2017)

Febuxostat Improves Uric Acid Levels and Renal Function in Patients with Chronic Kidney Disease and Hyperuricemia: A Meta-Analysis
por: Zheng, Yanqun, et al.
Publicado: (2022)

Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia
por: Gohda, Tomohito, et al.
Publicado: (2021)

Renal Cell Carcinoma with IVC Thrombi; Current Concepts and Future Perspectives
por: Nouh, Mohammed Ahmed Abdel-Muneem, et al.
Publicado: (2008)

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study
por: Tang, Honghu, et al.
Publicado: (2022)

Comparison of the Renoprotective Effect of Febuxostat for the Treatment of Hyperuricemia between Patients with and without Type 2 Diabetes Mellitus: A Retrospective Observational Study
por: Ito, Hiroyuki, et al.
Publicado: (2016)

Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: A 6-months open-label, randomized controlled trial
por: Mukri, Mohd Noor Azreey, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_thhlsk6v5rs3gs4haaiscdbcv5